medigraphic.com

2025, Number 1

<< Back Next >>

Rev Hematol Mex 2025; 26 (1)

Impact of MYC, BCL2, and/or BCL6 expression on the survival of patients with diffuse large B-cell lymphoma.

Rodríguez FKMR, Martínez MC, Montaño FEH, Navarrete PJJ, García CC, Reynaga KD, Zazueta PJF, Barranco LGI

Language: English
References: 15
Page: 1-7
PDF size: 392.58 Kb.


ABSTRACT

OBJECTIVE: To evaluate the prognostic significance of MYC, BCL2, and BCL6 expression in a Mexican cohort of patients with diffuse large B-cell lymphoma.
MATERIALS AND METHODS: A retrospective study including patients with de novo diffuse large B-cell lymphoma diagnosed at the Hospital General de Mexico between 2014 and 2018. Immunohistochemistry was used to assess protein expression, with positivity defined as > 40% for MYC, > 70% for BCL2, and > 50% for BCL6.
RESULTS: There were included 220 patients. Median age was 58 years, and 56.4% were male. MYC, BCL2, and BCL6 were positive in 30%, 27.3%, and 10% of cases, respectively. With a median follow-up of 19 months, the 3-year oaverall survival was significantly lower in MYC-positive vs negative cases and in BCL2-positive vs negative cases. Double-expressor lymphomas (MYC+/BCL2+) had the worst prognosis. BCL6 expression did not significantly impact overall survival. In multivariate analysis, extranodal disease and MYC+/BCL2+ status were independent predictors of poor overall survival.
CONCLUSIONS: MYC and BCL2 expression, individually and combined, are associated with inferior survival in Mexican patients with diffuse large B-cell lymphoma, underscoring the importance of routine immunohistochemical evaluation for risk stratification.


REFERENCES

  1. Hernandez-Ruiz E, Alvarado-Ibarra M, Lien-Chang LEJ, et al.Epidemiology and clinical characteristics of non-Hodgkinlymphoma in Mexico. World J Oncol 2021; 12 (1): 28-33.doi: 10.14740/wjon1351

  2. Susanibar-Adaniya S, Barta SK. 2021 Update on Diffuselarge B cell lymphoma: A review of current data and potentialapplications on risk stratification and management.Am J Hematol 2021; 96 (5): 617-29. doi: 10.1002/ajh.26151

  3. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmationof the molecular classification of diffuse large B-celllymphoma by immunohistochemistry using a tissuemicroarray. Blood 2004; 103 (1): 275-82. doi: 10.1182/blood-2003-05-1545

  4. Morrison VA. Frontline therapy with R-CHOP for diffuselarge B-cell lymphoma: Where have we come (or notcome)? A perspective. J Geriatr Oncol 2021; 12 (2): 320-5.doi: 10.1016/j.jgo.2020.09.015

  5. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revisionof the World Health Organization classification of lymphoidneoplasms Blood 2016; 127: 2375-90. http://dx.doi.org/10.1182/blood-2016-01-643569

  6. Swerdlow SH. Diagnosis of “double hit” diffuse large B-celllymphoma and B-cell lymphoma, unclassifiable, with featuresintermediate between DLBCL and Burkitt lymphoma:when and how, FISH versus IHC. Hematology 2014; 2014:90-9. https://dx.doi.org/10.1182/asheducation-2014.1.90

  7. Johnson NA, Slack GW, Savage KJ, Connors JM, et al. Concurrentexpression of MYC and BCL2 in diffuse large B-celllymphoma treated with rituximab plus cyclophosphamide,doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30 (28): 3452-9. doi: 10.1200/JCO.2011.41.0985

  8. Ye Q, Xu-Monette ZY, Tzankov A, et al. Prognostic impactof concurrent MYC and BCL6 rearrangements and expressionin de novo diffuse large B-cell lymphoma. Oncotarget2016; 7 (3): 2401-16.

  9. Zhang Y, Wang H, Ren C, et al. Correlation between C-MYC,BCL-2, and BCL-6 protein expression and gene translocationas biomarkers in diagnosis and prognosis of diffuse largeB-cell lymphoma. Front Pharmacol 2018; 9: 1497. https://doi.org.10.3389/fphar.2018.01497

  10. Cai Q, Medeiros LJ, Xu X, Young KH. MYC-driven aggressiveB-cell lymphomas: biology, entity, differential diagnosis andclinical management. Oncotarget 2015; 6 (36): 38591-616.doi: 10.18632/oncotarget.5774

  11. Horn H, Ziepert M, Becher C, et al. MYC status in concertwith BCL2 and BCL6 expression predicts outcome in diffuselarge B-cell lymphoma. Blood 2013; 121 (12): 2253-63. doi:10.1182/blood-2012-06-435842

  12. Ma Z, Niu J, Cao Y, et al. Clinical significance of “double-hit”and “double-expression” lymphomas. J Clin Pathol 2020; 73(3): 126-38. doi: 10.1136/jclinpath-2019-206199

  13. Huang S, Nong L, Wang W, et al. Prognostic impact of diffuselarge B-cell lymphoma with extra copies of MYC, BCL2and/or BCL6: comparison with double/triple hit lymphomaand double expressor lymphoma. Diagn Pathol 2019; 14(1): 81. doi: 10.1186/s13000-019-0856-7.

  14. Ting C-Y, Chang K-M, Kuan J-W, et al. Clinical significanceof BCL2, C-MYC, and BCL6 genetic abnormalities, Epstein-Barr virus infection, CD5 protein expression, germinalcenter B cell/non-germinal center B-cell subtypes, coexpressionof MYC/BCL2 proteins and co-expressionof MYC/BCL2/BCL6 proteins in diffuse large B-cell lymphoma:A clinical and pathological correlation study of120 patients. Int J Med Sci 2019; 16: 556-66. http://dx.doi.org/10.7150/ijms.27610

  15. Staiger AM, Ziepert M, Horn H, et al. Clinical impactof the cell-of-origin classification and the MYC/BCL2dual expresser status in diffuse large B-cell lymphomatreated within prospective clinical trials of the GermanHigh-Grade Non-Hodgkin’s Lymphoma Study Group. JClin Oncol 2017; 35: 2515-26. http://dx.doi.org/10.1200/jco.2016.70.3660




2020     |     www.medigraphic.com